ATE361934T1 - Verfahren zur modulierung der aktivität von th2- zellen durch modulierung der aktivität von xbp-1 - Google Patents

Verfahren zur modulierung der aktivität von th2- zellen durch modulierung der aktivität von xbp-1

Info

Publication number
ATE361934T1
ATE361934T1 AT00988444T AT00988444T ATE361934T1 AT E361934 T1 ATE361934 T1 AT E361934T1 AT 00988444 T AT00988444 T AT 00988444T AT 00988444 T AT00988444 T AT 00988444T AT E361934 T1 ATE361934 T1 AT E361934T1
Authority
AT
Austria
Prior art keywords
xbp
activity
modulating
methods
hepatocyte growth
Prior art date
Application number
AT00988444T
Other languages
English (en)
Inventor
Laurie Glimcher
Andreas Reimold
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Application granted granted Critical
Publication of ATE361934T1 publication Critical patent/ATE361934T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/973—Simultaneous determination of more than one analyte

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Environmental Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
AT00988444T 1999-12-30 2000-12-29 Verfahren zur modulierung der aktivität von th2- zellen durch modulierung der aktivität von xbp-1 ATE361934T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17393199P 1999-12-30 1999-12-30

Publications (1)

Publication Number Publication Date
ATE361934T1 true ATE361934T1 (de) 2007-06-15

Family

ID=22634110

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00988444T ATE361934T1 (de) 1999-12-30 2000-12-29 Verfahren zur modulierung der aktivität von th2- zellen durch modulierung der aktivität von xbp-1
AT05013817T ATE551358T1 (de) 1999-12-30 2000-12-29 Verfahren und zusammensetzungen zur modulierung des hepatozytenwachstums, der differenzierung von plasmazellen oder der aktivität von t-zellen durch modulierung der aktivität von xbp-1

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT05013817T ATE551358T1 (de) 1999-12-30 2000-12-29 Verfahren und zusammensetzungen zur modulierung des hepatozytenwachstums, der differenzierung von plasmazellen oder der aktivität von t-zellen durch modulierung der aktivität von xbp-1

Country Status (12)

Country Link
US (3) US6632608B2 (de)
EP (2) EP1254169B1 (de)
JP (1) JP2003518942A (de)
AT (2) ATE361934T1 (de)
AU (3) AU784883B2 (de)
CA (1) CA2396062C (de)
DE (1) DE60034817T2 (de)
DK (1) DK1254169T3 (de)
ES (1) ES2283340T3 (de)
MX (1) MXPA02006433A (de)
PT (1) PT1254169E (de)
WO (1) WO2001049717A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003303082B2 (en) 2002-01-30 2009-07-02 Dana-Farber Cancer Institute, Inc. Compositions and methods related to TIM-3, a Th1-specific cell surface molecule
US7666587B2 (en) * 2002-04-12 2010-02-23 New York University Method of screening test substances for treating or preventing a disease mediated by plasma cells
JP2006515154A (ja) * 2002-06-21 2006-05-25 セントカー・インコーポレーテツド モノクローナル抗体の作成方法
AU2003268356A1 (en) * 2002-08-30 2004-03-19 President And Fellows Of Harvard College Methods and compositions for modulating xbp-1 activity
WO2005078098A1 (en) * 2004-02-12 2005-08-25 The Walter And Eliza Hall Institute Of Medical Research Modified cells that co-express blimp1 and a reporter molecule and methods of using the same
WO2006031930A2 (en) * 2004-09-15 2006-03-23 The President And Fellows Of Harvard College Modulation of xbp-1 activity for treatment of metabolic disorders
US20060063187A1 (en) * 2004-09-15 2006-03-23 Hotamisligil Gokhan S Modulation of XBP-1 activity for treatment of metabolic disorders
AU2006305754A1 (en) * 2005-10-28 2007-05-03 Centocor, Inc. Use of B cell expansion agents in generating antibodies
CA2606634A1 (en) * 2006-12-08 2008-06-08 Centenary Institute Of Cancer Medicine And Cell Biology Assay for response to proteasome inhibitors
US8227184B2 (en) * 2008-01-14 2012-07-24 President And Fellows Of Harvard College Methods for modulating de novo hepatic lipogenesis by modulating XBP-1 activity
WO2010088498A1 (en) * 2009-01-30 2010-08-05 Bayer Healthcare Llc Methods for treating estrogen receptor positive cancer by x-box binding protein 1 inhibition
US9956236B2 (en) 2011-02-07 2018-05-01 Cornell University Methods for increasing immune responses using agents that directly bind to and activate IRE-1
WO2013134774A1 (en) 2012-03-09 2013-09-12 Cornell University Modulation of breast cancer growth by modulation of xbp1 activity
ES2724300T3 (es) 2013-09-25 2019-09-10 Univ Cornell Compuestos para inducir inmunidad antitumoral y métodos de lo mismo
KR101864410B1 (ko) * 2016-01-21 2018-06-05 한국화학연구원 3차원 간세포 배양 유닛, 간독성 평가 시스템 및 이를 이용한 간독성 평가 방법
JP7126084B2 (ja) 2017-06-01 2022-08-26 コーネル ユニバーシティー Ｉｒｅ１小分子阻害薬
US10392367B2 (en) 2017-06-01 2019-08-27 Quentis Therapeutics, Inc. IRE1 small molecule inhibitors
WO2020011909A1 (en) * 2018-07-11 2020-01-16 Secarna Pharmaceuticals Gmbh & Co. Kg Nucleic acid polymers inhibiting the expression of xbp1

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3681787D1 (de) 1985-07-05 1991-11-07 Whitehead Biomedical Inst Expression von fremdem genetischem material in epithelzellen.
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
DE122007000007I2 (de) 1986-04-09 2010-12-30 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
WO1989002468A1 (en) 1987-09-11 1989-03-23 Whitehead Institute For Biomedical Research Transduced fibroblasts and uses therefor
DE3851153T2 (de) 1987-12-11 1995-01-05 Hughes Howard Med Inst Genetische modifizierung von endothelialen zellen.
EP0732397A3 (de) 1988-02-05 1996-10-23 Whitehead Institute For Biomedical Research Modifizierte Hepatozyten und deren Verwendungen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (de) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Verfahren zur herstellung von spezifischen bindungspaargliedern
ES2115662T3 (es) 1990-10-31 1998-07-01 Cell Genesys Inc Modificacion genetica de celulas endoteliales.
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
ATE363532T1 (de) 1991-03-01 2007-06-15 Dyax Corp Verfahren zur herstellung bindender miniproteine
ATE269401T1 (de) 1991-04-10 2004-07-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
DE69334150T2 (de) 1992-05-14 2008-03-13 Baylor College Of Medicine, Houston Mutierte steroidhormonrezeptoren, methoden für ihre benutzung und molekularer schalter für gentherapie
CA2137558A1 (en) 1992-07-17 1994-02-03 Wayne A. Marasco Method of intracellular binding of target molecules
DE69435260D1 (de) 1993-02-12 2010-02-11 Univ R Regulierte transkription von zielgerichteten genen und andere biologische ereignisse
US5866755A (en) 1993-06-14 1999-02-02 Basf Aktiengellschaft Animals transgenic for a tetracycline-regulated transcriptional inhibitor
US5650298A (en) 1993-06-14 1997-07-22 Basf Aktiengesellschaft Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
AU682206B2 (en) 1993-07-30 1997-09-25 Thomas Jefferson University Intracellular immunization
US5491084A (en) 1993-09-10 1996-02-13 The Trustees Of Columbia University In The City Of New York Uses of green-fluorescent protein
US5840832A (en) * 1994-10-21 1998-11-24 The Johns Hopkins University Transcription factor regulating MHC expression, CDNA and genomic clones encoding same and retroviral expression constructs thereof
DK0815257T3 (da) 1995-01-31 2002-04-22 Bioimage As Fremgangsmåde til karakterisering af biologisk aktive stoffer
EP0857780A4 (de) * 1995-09-14 2001-12-05 Sumitomo Electric Industries Neue proteine die ausgezeichnet in leberkrebs expremiert werden, gene die diese proteine kodieren, antikörper gagegen und geeignete methoden
ATE259419T1 (de) * 1996-03-15 2004-02-15 Munin Corp Humanes cyr61, ein signalmolekül der extrazellulaeren matrix
EP0891425A2 (de) * 1996-04-23 1999-01-20 President And Fellows Of Harvard College Methode und zusammensetzungen für die regulierung von t-zelluntereinheiten durchdie modulation von der transkriptionsfaktoraktivität
US5945307A (en) * 1998-01-26 1999-08-31 Millennium Pharmaceuticals, Inc. Isolated nucleic acid molecules encoding a G-protein coupled receptor showing homology to the 5HT family of receptors
AU2003268356A1 (en) * 2002-08-30 2004-03-19 President And Fellows Of Harvard College Methods and compositions for modulating xbp-1 activity

Also Published As

Publication number Publication date
US6632608B2 (en) 2003-10-14
PT1254169E (pt) 2007-08-21
EP1254169B1 (de) 2007-05-09
WO2001049717A3 (en) 2001-12-06
EP1626056A2 (de) 2006-02-15
ATE551358T1 (de) 2012-04-15
CA2396062C (en) 2009-11-17
DK1254169T3 (da) 2007-08-06
DE60034817T2 (de) 2008-01-31
AU2006202243B2 (en) 2010-06-03
US7358415B2 (en) 2008-04-15
US20020059652A1 (en) 2002-05-16
EP1254169A2 (de) 2002-11-06
DE60034817D1 (de) 2007-06-21
ES2283340T3 (es) 2007-11-01
EP1626056A3 (de) 2006-05-03
AU2006202243A1 (en) 2006-06-22
EP1626056B1 (de) 2012-03-28
US20040110236A1 (en) 2004-06-10
MXPA02006433A (es) 2002-11-29
US20080241114A1 (en) 2008-10-02
CA2396062A1 (en) 2001-07-12
AU2465301A (en) 2001-07-16
AU2010219305A1 (en) 2010-09-30
AU784883B2 (en) 2006-07-20
WO2001049717A2 (en) 2001-07-12
JP2003518942A (ja) 2003-06-17

Similar Documents

Publication Publication Date Title
ATE361934T1 (de) Verfahren zur modulierung der aktivität von th2- zellen durch modulierung der aktivität von xbp-1
Plachta et al. Oct4 kinetics predict cell lineage patterning in the early mammalian embryo
Beck et al. Extraembryonic proteases regulate Nodal signalling during gastrulation
Reinheckel et al. The lysosomal cysteine protease cathepsin L regulates keratinocyte proliferation by control of growth factor recycling
Cinco et al. Spatial characterization of bioenergetics and metabolism of primordial to preovulatory follicles in whole ex vivo murine ovary
ATE553187T1 (de) Konditioniertes zellkulturmedium, verfahren zur herstellung und dessen verwendung zur haltung, proliferation und differenzierung von säugetierzellen
CY1107689T1 (el) Μεθοδοι και μεσα ελεγχου της σιαλιωσης πρωτεινων που παραγονται απο κυτταρα θηλαστικων
EP1546162A4 (de) Auf lumineszenz basierende verfahren und sonden zur messung der cytochrom-p450-aktivitüt
ATE87213T1 (de) Potenzierung der erythropoiesis.
ATE454632T1 (de) Verfahren zur beurteilung der lebensfähigkeit von embryos
NO971245L (no) In vitro-modeller for sentralnervesystemfunksjon og -dysfunksjon
Meng et al. Taste bud-derived BDNF is required to maintain normal amounts of innervation to adult taste buds
BR0101294A (pt) Métodos de triagem de um composto que modula a atividade do canal de cálcio, e para bloqueadores e para estimuladores de icrac, kit para uso em um método, célula sanguìnea ou célula derivada do sangue, linfócito ou célula derivada de linfócito, ou mastócito ou célula derivada de mastócito, e, população de células imunes de roedores
WO2004103394A3 (en) Method and compositions for nerve regeneration
Antonov et al. Current state-of-the-art and unresolved problems in using human induced pluripotent stem cell-derived dopamine neurons for parkinson’s disease drug development
Aoki et al. Cooperative and indispensable roles of endothelin 3 and KIT signalings in melanocyte development
ATE388223T1 (de) Verfahren zur differenzierung einer mesenchym- stammzelle zu einer nervenzelle sowie die nervenzelle enthaltende pharmazeutische zusammensetzung gegen eine neurodegenerative krankheit
ATE505539T1 (de) Verfahren zur förderung des überlebens und/oder der proliferation einer neuralen stammzelle und zur förderung der neuritenverlängerung, promotor dafür, die neurale stammzelle enthaltende pharmazeutische zusammensetzung, testverfahren und screening-verfahren
DE602004026445D1 (de) Verwendung von cardiotrophin zur modulation der stammzellenproliferation
ATE478156T1 (de) Verfahren zur identifizierung von modulatoren der eoxin-bildung
ATE456797T1 (de) Verwendung von nogo-c bei der beurteilung von herzversagen
DK1644485T3 (da) Udskilte proteiner som markører for celledifferentiering
DE69128181D1 (de) Enzymtests
Porterfield et al. Characterization of oxygen and calcium fluxes from early mouse embryos and oocytes
ATE483793T1 (de) Zusammensetzung einer modifizierten rekonstituierten basalmembran für testsysteme

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1254169

Country of ref document: EP